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Summary Objectives The maximum tolerated dose (MTD)
and overall safety of sunitinib plus pemetrexed and carboplatin
was determined in patients with advanced solid malignancies.
Methods In this phase I dose-escalation study, patients received
oral sunitinib on a continuous daily dosing (CDD) schedule
(37.5 mg/day) or Schedule 2/1 (2 weeks on treatment, 1 week
off treatment; 37.5 or 50 mg/day). Pemetrexed (400–500 mg/
m2 IV) and carboplatin (AUC=5 mg·min/ml IV) were admin-
istered q3w. At the MTD for the chosen schedule, a cohort of
patients with non-small cell lung cancer (NSCLC) or mesothe-
lioma was further evaluated. Results Twenty-one patients were
enrolled on Schedule 2/1 (expansion cohort included) and 3
patients on the CDD schedule. The MTD on Schedule 2/1 was
sunitinib 37.5 mg/day with pemetrexed 500 mg/m2 and
carboplatin AUC=5 mg·min/ml; MTD on the CDD schedule
was not established. Dose-limiting toxicities included grade 3/4
neutropenia, grade 3 thrombocytopenia, and grade 3 hand–foot
syndrome. The most common grade 3/4 drug-related non-
hematologic adverse events at Schedule 2/1 MTD were
fatigue/asthenia and diarrhea (both n=4). Grade 3/4 hemato-
logic abnormalities included neutropenia (83 %) and leukope-
nia (83 %). Pharmacokinetic data revealed no clinically signif-
icant drug–drug interactions. Best response at the Schedule 2/1
MTD was stable disease ≥8 weeks in 3/5 evaluable patients
(60 %). Conclusions With this combination, in patients with
advanced solid malignancies, sunitinib MTD on Schedule 2/1
was 37.5 mg/day. Sunitinib plus pemetrexed and carboplatin
were tolerable at the MTD, although sunitinib dose delays and
reductions were often required due to myelosuppression.
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Introduction
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of
vascular endothelial growth factor receptors (VEGFRs 1–3)
and platelet-derived growth factor receptors (PDGFRs α and
β), as well as other receptors [1–6]. VEGF and PDGF are key
angiogenic ligands that influence cancer growth, progression,
and metastasis [7–10]. Sunitinib is approved multinationally
for the treatment of advanced renal cell carcinoma (RCC) and
imatinib-resistant or -intolerant gastrointestinal stromal tu-
mors (GISTs) [11]. In a phase II trial, single-agent sunitinib
was well tolerated and associated with an encouraging re-
sponse rate (11.1 %) in patients with previously treated ad-
vanced non-small cell lung cancer (NSCLC) [12, 13] and has
also shown antitumor activity in patients with other solid
malignancies, such as pancreatic neuroendocrine tumor,
sarcoma, thyroid cancer, and melanoma [14, 15]. Both
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intermittent and continuous daily dosing (CDD) schedules of
sunitinib have shown similar efficacy and tolerability in pa-
tients with RCC, GIST, and NSCLC. The approved dose for
RCC and GIST is 50 mg/day administered in 6-week cycles
comprising 4 weeks on treatment followed by 2 weeks off
treatment (Schedule 4/2), and the approved dose for pancre-
atic NET is 37.5 mg/day CDD [12, 13, 16–19].
Pemetrexed is a chemotherapeutic agent that targets multi-
ple folate pathway enzymes resulting in inhibition of cellular
replication. It has clinical activity in a range of solid tumors
[20]. While single-agent pemetrexed is approved for second-
line or maintenance treatment of patients with non-squamous
advanced NSCLC, response rates in the second-line setting
remain low (<10 %) and there is a need for treatment combi-
nations with improved efficacy [21, 22]. Pemetrexed in com-
bination with carboplatin is active in multiple tumor types
including NSCLC, small-cell lung cancer, and mesothelioma,
and has different toxicities than pemetrexed with cisplatin
[23–25].
The addition of antiangiogenic agents to chemotherapy
has shown additive or synergistic effects in preclinical
models [26–28]. Changes in tumor vasculature initiated by
antiangiogenic agents appear to enhance chemotherapy dif-
fusion and delivery, possibly by reducing interstitial pressure
and increasing permeability and perfusion [7, 29]. Sunitinib
combined with pemetrexed decreased tumor growth in
NSCLC NCI-H460 xenograft models [26], although a recent
phase II study in patients with advanced NSCLC did not
show a benefit for the combination over pemetrexed alone as
second-line therapy [30]. Clinical evidence from other
antiangiogenic agents, such as the anti-VEGF monoclonal
antibody bevacizumab, further support the benefit of combi-
nation therapy versus chemotherapy alone in patients with
solid tumors including advanced non-squamous NSCLC [31,
32] and colorectal cancer [33].
The primary objective of this phase I dose-escalation study
was to determine the maximum tolerated dose (MTD) and
overall safety of sunitinib (on intermittent and CDD sched-
ules) in combination with pemetrexed and carboplatin in
patients with advanced solid malignancies.
Methods
Study population
Patients aged 18 years or older with Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1 were
enrolled. Patients had a histologic or cytopathologic diagnosis
of solid malignancy refractory to standard therapy or for which
no standard therapy existed, adequate organ function (including
bone marrow, kidney, and liver), and a life expectancy of
≥12 weeks. In the expansion cohort, previously treated and/or
platinum- refractory/-intolerant patients with recurrent or ad-
vanced NSCLC of any histologic subtype and patients with
advanced unresectable mesothelioma (pleural or peritoneal;
stage 3 or 4) were eligible for enrollment.
Patients were excluded if they had uncontrolled or symp-
tomatic brain metastases; gross hemoptysis (≥5ml per episode
or ≥10 ml per day) within 4 weeks of study start; uncontrolled
hypertension (>150/100 mmHg) despite standard antihyper-
tensive agents; or cardiac disease, cerebrovascular accident or
pulmonary embolism within 12 months of starting the study.
Other exclusion criteria included: National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE) grade 3 hemorrhage within 4 weeks of treatment;
ongoing cardiac dysrhythmias of grade ≥2; atrial fibrillation of
any grade; prolongation of the QTc interval (>450 ms for
males or >470 ms for females); chemotherapy, surgery or
radiation therapy less than 4 weeks before study start (except
palliative radiotherapy to non-target lesions); known hyper-
sensitivity to carboplatin; or prior treatment with pemetrexed,
carboplatin, or sunitinib.
Study design and treatment
This open-label, multicenter, phase I trial (NCT00528619)
conducted in the US and Canada investigated escalating doses
of sunitinib plus pemetrexed and carboplatin in combination
in serial patient cohorts. The primary objective was determi-
nation of theMTD and overall safety of sunitinib administered
in combination with pemetrexed and carboplatin in patients
with advanced solid malignancies for which curative therapy
was not available. Secondary endpoints included pharmaco-
kinetic (PK) parameters and the preliminary antitumor activity
of this combination.
Sunitinib (37.5 or 50 mg) was administered orally once
daily on either the CDD schedule or Schedule 2/1 (2 weeks on
treatment followed by 1 week off treatment). Pemetrexed
(400–500 mg/m2 IV) and carboplatin (AUC=5 mg·min/ml
IV) were administered once every 3 weeks (q3w). Planned
dose escalation cohorts (Table 1) followed a standard 3+3
design and began with the CDD schedule. The dose levels
were based on the previous MTD determinations for sunitinib
in combination with pemetrexed (i.e., sunitinib 37.5 mg/day
on the CDD schedule and 50 mg/day on Schedule 2/1;
pemetrexed 500 mg/m2) [34].
Treatment cycles lasted 3 weeks, and patients received up
to six cycles of triple combination treatment. Upon study
completion, patients who continued to experience clinical
benefit were eligible to enter a continuation study to receive
sunitinib either alone or together with any or all components
of the original treatment combination, at the investigator’s
discretion. Patients with RECIST-defined progressive disease
but who were judged as benefiting from treatment were also
eligible to enroll into the continuation protocol.
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The MTD was defined as the highest dose at which 0/3 or
≤1/6 patients experienced a dose-limiting toxicity (DLT) dur-
ing the first 22 days of treatment, with the next higher dose
level having at least 2/3 or 2/6 patients with a DLT. DLTs were
defined as grade 3 or 4 drug-related toxicities that occurred
during the defined time frame or that resulted in a delay in
administering cycle 2. Hematologic DLTs were defined as
neutropenia (grade ≥3 with grade ≥3 infection; grade 4 lasting
≥7 days or with fever >38.5 °C lasting >24 h), thrombocyto-
penia (grade ≥3 with bleeding or grade 4 for ≥7 days), or
lymphopenia accompanied by an opportunistic infection.
Nonhematologic DLTs included grade 3/4 toxicities lasting
≥7 days. Nausea, vomiting, and diarrhea that persisted at grade
3/4 despite maximal medical therapy were also considered
DLTs.
Depending on the safety profiles of the CDD schedule and
Schedule 2/1, one dosing schedule could be further explored
in a separate cohort of up to an additional 10 patients with
NSCLC and up to 10 patients with mesothelioma (the expan-
sion cohort) treated at the MTD.
All patients provided written informed consent. The study
was approved by the institutional review board of each par-
ticipating center and was carried out in accordance with the
International Conference on Harmonization Good Clinical
Practice guidelines, and applicable local laws and regulatory
requirements.
Study assessments
Safety was evaluated at each patient visit by the assessment of
adverse events (AEs; NCI CTCAE version 3.0), laboratory
abnormalities, physical examinations, and vital signs. Electro-
cardiogram profiles were obtained at baseline and cycle 1. The
AEs related to each study drug were evaluated to determine
the safety of the triple combination.
Full PK profiles for sunitinib, SU12662 (its primary active
metabolite), the sum of sunitinib plus SU12662, pemetrexed,
and carboplatin (as total and free [unbound] platinum) were
obtained from the last 3 patients enrolled in the Schedule 2/1
MTD cohort. Pemetrexed and carboplatin PK samples were
collected on cycle 1 day 1 (i.e., in the absence of sunitinib) and
cycle 2 day 1 (in the presence of sunitinib). Sunitinib PK
samples were collected on cycle 2 day 1. To obtain steady-
state values, only patients who received at least 10 consecutive
doses of sunitinib prior to sample collection on cycle 2 day 1
were included in the summary. Similarly, for the sunitinib PK
data used as reference (historical control, NSCLC patients
receiving sunitinib as single therapy) only patients who re-
ceived at least 10 consecutive doses of sunitinib prior to
sample collection were included. Pharmacokinetic parameters
were estimated using non-compartmental methods, and in-
cluded Cmax (maximum plasma concentration), Tmax (time to
Cmax), AUC24 (area under the plasma concentration–time
curve from time zero to 24 h), AUC∞ (AUC from time zero
to infinity), CL (clearance), and t½ (terminal phase half-life).
Computed tomography (CT) or magnetic resonance imag-
ing (MRI) scans were performed at screening, at every even-
numbered cycle, whenever disease progression was suspected
or to confirm a response, and at the end of treatment/
withdrawal from the study. Brain CTorMRI and/or bone scan
were performed as clinically indicated. In patients with mea-
surable disease, objective response was determined according
to Response Evaluation Criteria in Solid Tumors (RECIST
version 1.0) [35].
Statistical methods
Due to the exploratory nature of this study, no confirmatory
inferential statistical analyses were planned. Descriptive sta-
tistics were used to summarize all patient characteristics,




Three patients were enrolled into the CDD and 15 into the
Schedule 2/1 dose-escalation cohorts (Table 1). An additional
6 patients with NSCLC (n=5) and mesothelioma (n=1) were
subsequently enrolled into the expansion cohort on Schedule
2/1 (see below). In the expansion cohort, all 6 patients had
undergone previous surgery and 4 had undergone prior radi-
ation therapy. One had received prior systemic treatment (1
regimen). The median duration since first diagnosis was
1.7 months (range, 0.3–5.0) for the patients with NSCLC
and 3.5 months for the patient with mesothelioma. In total,
these 24 patients received 98 cycles of sunitinib therapy, 99
cycles of pemetrexed therapy, and 99 cycles of carboplatin
therapy (Table 1). Patient demographic and baseline charac-
teristics are summarized in Table 2.
Safety
Schedule 2/1
The MTD on Schedule 2/1 was determined to be sunitinib
37.5 mg/day + pemetrexed 500 mg/m2 + carboplatin AUC=5-
mg·min/ml. At the Schedule 2/1 MTD, one DLT of grade 3
neutropeniawas observed (Table 3). In the escalation cohort above
this dose (sunitinib 50 mg/day + pemetrexed 500 mg/m2 +
carboplatin AUC=5 mg·min/ml), DLTs of grade 3 thrombo-
cytopenia (n=1) and grade 4 neutropenia (n=2) were ob-
served (Table 3).
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In total, 9/12 patients (75 %) treated at the Schedule 2/1
MTD had at least one sunitinib dose delay, with 1 patient
(8 %) having a delay of 3–4 weeks. Additionally, 6 patients
(50 %) in this cohort had a sunitinib dose reduction to 25 mg.
Six patients discontinued sunitinib at the MTD due to AEs
(neutropenia [n=3], fatigue, diarrhea, and clostridial infection
[all n=1]). The diarrhea was considered by the investigator to
be related to sunitinib and pemetrexed, while the neutropenia
and fatigue were attributed to all three study treatments. The
median number of cycles of sunitinib, pemetrexed, and
carboplatin received per patient was 5.0 (range 2–6) in the
original Schedule 2/1 MTD cohort (n=6), and 3.5 (range 1–4)
in the expansion cohort (n=6; Table 1). The dose of sunitinib
was reduced to 25 mg in 2 patients (33 %) in the original
Schedule 2/1 MTD cohort and 4 patients (67 %) in the
expansion cohort (Table 1). Of these 6 patients, four
discontinued sunitinib within 12 weeks after dose reduction,
while the other two continued for 13–24 weeks. The dose of
pemetrexed was reduced to 400 mg/m2 in 3 patients (50 %) in
the Schedule 2/1 MTD cohort and 4 patients (67 %) in the
expansion cohort. All but one discontinued pemetrexedwithin
12 weeks after dose reduction. The dose of carboplatin was
reduced up to 30 % in 3 patients (50 %) in the Schedule 2/1
MTD cohort and 5 patients (83 %) in the expansion cohort. Of
these 8 patients, four discontinued carboplatinwithin 12weeks
after dose reduction, and the other four continued for 13–
24 weeks.
One patient with NSCLC tolerated 37.5 mg for 3 cycles but
was discontinued from the study due to diarrhea related to
sunitinib and pemetrexed. One patient with anal cancer re-
ceived sunitinib 50 mg for 4 cycles but the pemetrexed dose
had to be reduced to 375 mg/m2 in Cycles 2 through 4.
Another patient with metastatic synovial sarcoma received
sunitinib 50 mg for 3 cycles, but the pemetrexed dose had to
be reduced to 400 mg/m2 in Cycles 2 and 3.
The most common treatment-related non-hematologic
AEs at the MTD on Schedule 2/1 are shown in Table 4;
these events were predominantly mild to moderate in se-
verity. In the original Schedule 2/1 MTD cohort, the most
common non-hematologic AEs related to any study drug
were fatigue/asthenia and diarrhea (both n=4; 67 %).
Among patients in the expansion cohort, fatigue/asthenia
(n=6; 100 %), nausea, and decreased appetite (each n=5;
83 %) were most common. Hematologic laboratory abnor-
malities on Schedule 2/1 at the MTD were grade 3/4
neutropenia, n=5 (83 %); grade 3 leukopenia, n=5
(83 %); grade 3 lymphopenia, n=1 (17 %); grade 3/4
thrombocytopenia, n=3 (50 %); and grade 3 anemia, n=3
(50 %). Serious AEs considered related to sunitinib treat-
ment at the MTD included febrile neutropenia (n=3), neu-
tropenia (DLT), transient ischemic attack, anemia, and di-
arrhea (each n=1). No patient at the MTD had more than
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CDD schedule
On theCDD schedule, twoDLTs of grade 3 hand–foot syndrome
(n=1) and grade 4 neutropenia (n=1) were observed with
sunitinib 37.5 mg/day + pemetrexed 400 mg/m2 + carboplatin
AUC=5mg·min/ml (Table 3). Because lower doses of sunitinib,
pemetrexed, or carboplatin were considered unlikely to be effi-
cacious, no further dose levels were investigated on the CDD
schedule (thus the CDD MTD was not established) and the
Schedule 2/1 MTD was selected for the expansion cohort.
On the CDD schedule, the median number of cycles of
sunitinib, pemetrexed, and carboplatin received per patient was
6.0 (4–6), and dose reductions occurred in 2 patients (67 %) for
sunitinib, and in 1 patient each for pemetrexed and carboplatin at
dose level 1B (Table 1). Three patients on the CDD schedule
(100%) had at least one sunitinib dose delay of 1–3weeks, and 2
patients had a sunitinib dose reduction to 25mg.Most treatment-
related non-hematologic AEs were grade 1 or 2, with increased
lacrimation being the most common (n=3). Three serious AEs
were considered related to sunitinib treatment: anemia, dehydra-
tion, and fatigue. Hematologic laboratory abnormalities were
grade 4 neutropenia, n=3 (100 %); grade 3/4 leukopenia, n=3
(100 %); grade 3 lymphopenia, n=1 (33 %); grade 3 anemia,
n=2 (67 %); and grade 4 thrombocytopenia, n=1 (33 %).
All cohorts
Across all cohorts there were three deaths (one in the MTD
cohort on Schedule 2/1 and two in the sunitinib 50 mg/day +
pemetrexed 500 mg/m2 + carboplatin AUC=5 mg·min/ml
cohort on Schedule 2/1). All deaths occurred during follow-
up, more than 28 days after the last dose of study medication,
and were considered related to the disease under study.
Pharmacokinetics
Pharmacokinetic data revealed no clinically significant drug–
drug interactions with the triple combination of sunitinib,
pemetrexed, and carboplatin. The PK profile of sunitinib plus









37.5 400 5 3 –
37.5b 500b 5b 6 Grade 3 neutropenia (n=1)
50 500 5 6 Grade 3 thrombocytopenia (n=1)
Grade 4 neutropenia (n=2)
CDD schedule (n=3)
37.5 400 5 3 Grade 3 hand–foot syndrome (n=1)
Grade 4 neutropenia (n=1)
CDD continuous daily dosing; DLT dose-limiting toxicity
a If a DLT was experienced by only one of the three patients at any dose
level, the cohort was expanded to six patients. If none of the additional
three patients experienced a DLT, the dose was escalated to the next level.
If DLTs occurred in ≥2 patients at any dose level, the dose level was
deemed as having exceeded the MTD and the prior, lower dose level was
further expanded (if only three patients were previously treated at that
dose level). The MTD was defined as the dose level at which no more
than one patient in a cohort of six experienced a DLT during the first
22 days of treatment of each schedule
bMaximum tolerated dose (MTD)
Table 4 Treatment-related (sunitinib, pemetrexed or carboplatin) non-
hematologic adverse events of special interest or experienced by ≥2
patients treated at the maximum tolerated dose on Schedule 2/1
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Fatigue/asthenia 1 (17) 4 (67) 1 (17) 6 (100)
Decreased appetite 0 2 (33) 1 (17) 5 (83)
Nausea 0 1 (17) 1 (17) 5 (83)
Diarrhea 1 (17) 4 (67) 1 (17) 4 (67)
Edema/swellinga 0 2 (33) 0 4 (67)
Dyspepsia 0 1 (17) 0 3 (50)
Dehydration 0 0 2 (33) 3 (50)
Hypertension 0 2 (33) 0 2 (33)
Skin/subcutaneous tissue disordersb 0 2 (33) 0 2 (33)
Weight decreased 0 1 (17) 0 2 (33)
Chills 0 0 0 2 (33)
Vomiting 0 0 0 2 (33)
Yellow skin 0 0 0 2 (33)
Hypomagnesemia 0 2 (33) 0 1 (17)
Stomatitis/oral discomfort/
related oral syndromesc
0 2 (33) 0 1 (17)
Paresthesia/neuropathyd 0 1 (17) 0 1 (17)
Constipation 0 2 (33) 0 0
Flatulence 0 2 (33) 0 0
Jaundice 0 2 (33) 0 0
No grade 5 adverse events were reported at the MTD on Schedule 2/1
MTD maximum tolerated dose
a Edema/swelling is any event having a preferred term that contains
edema or swelling
b Skin/subcutaneous tissue disorders is any event having a preferred term
that contains erythema or hyperkeratosis or rash or skin exfoliation or skin
hyperpigmentation
c Stomatitis/oral discomfort/related oral syndromes is any event having a
preferred term equal to aphthous stomatitis, gingival pain, gingival ulcer-
ation, gingivitis, glossodynia, glossitis, mouth ulceration, mucosal dry-
ness, mucosal inflammation, mucosal ulceration, oral discomfort, oral
mucosal blistering, oral pain, stomatitis, swollen tongue, tongue blister-
ing, tongue edema, or tongue ulceration
d Paresthesia/neuropathy is any event having a preferred term that con-
tains paresthesia or neuropathy
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SU12662 in the presence of pemetrexed/carboplatin was
compared with historical controls since no data were col-
lected for sunitinib administered alone (Table 5). Samples
from the last 3 patients enrolled in the Schedule 2/1 MTD
cohort showed that the geometric mean ratios (triple com-
bination relative to sunitinib alone) for sunitinib Cmax and
AUC24 were 1.12 and 1.38, respectively. These data sug-
gest that the PK of sunitinib when co-administered with
pemetrexed and carboplatin were similar to when it was
administered alone. The geometric mean ratios (triple com-
bination relative to pemetrexed/carboplatin alone) for
pemetrexed Cmax and AUC∞ were 1.20 and 1.03, respec-
tively; for total platinum Cmax and AUC24 they were 0.97
and 1.00; and for free platinum Cmax and AUC24 they
were 0.94 and 0.95 (Table 5). Based on these data, the
addition of sunitinib to pemetrexed and carboplatin did not
appear to affect the PK of pemetrexed or carboplatin.
Individual patient plasma concentration–time profiles are
presented in Fig. 1.
Antitumor activity
Schedule 2/1
Of 21 evaluable patients treated on Schedule 2/1, a confirmed
partial response was observed in 4 patients (objective re-
sponse rate [ORR] 19.0 %) and stable disease ≥8 weeks was
reported in 9 patients (42.9 %). The patients with a partial
response had primary diagnoses of breast cancer (sunitinib
37.5 mg + pemetrexed 400 mg/m2 + carboplatin AUC=5-
mg·min/ml), esophageal carcinoma (sunitinib 37.5 mg +
pemetrexed 500 mg/m2 + carboplatin AUC=5 mg·min/ml),
gastric cancer (sunitinib 50 mg + pemetrexed 500 mg/m2 +
carboplatin AUC=5 mg·min/ml), and NSCLC, tumor histol-
ogy not otherwise specified (NOS; sunitinib 50 mg +
pemetrexed 500 mg/m2 + carboplatin AUC=5 mg·min/ml).
Of 5 patients with NSCLC treated at the Schedule 2/1
MTD who were evaluable based on measurable disease at
baseline, three had stable disease ≥8 weeks, one had progres-
sive disease, and in one case the response could not be
evaluated (stable disease but <8 weeks for response evalua-
tion) (Table 6). As part of a continuation protocol, sunitinib
(25–50 mg/day) was administered to 3 patients with NSCLC
upon completion of 6 cycles of sunitinib + pemetrexed +
carboplatin in the original study, or at the investigator’s dis-
cretion. Best overall responses (taking into account time spent
on both the original and continuation protocols) were partial
response in 1 patient maintained for 6.9 months and stable
disease maintained for 3.5 months and 7.9 months in the other
2 patients. Overall survival times were greater than 10.0, 6.9,
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CDD schedule
All 3 evaluable patients treated with the triple combination on
the CDD schedule had stable disease ≥8 weeks as the best
confirmed objective response.
Discussion
Data from preclinical tumor models suggest that adding an
antiangiogenic agent to chemotherapy may improve efficacy
[26–28]. Pemetrexed, sunitinib, and carboplatin are well tol-
erated individually and in combination, and have demonstrat-
ed antitumor activity in a broad range of malignancies, includ-
ing NSCLC [12, 13, 22, 25]. The combination of pemetrexed
and sunitinib has previously been reported to have promising
tolerability and the potential for clinical benefit in patients
with solid tumors, including NSCLC [34]. However, as noted
above, a randomized phase II study of pemetrexed versus
sunitinib versus the combination conducted by CALGB sug-
gested that single agent pemetrexed was superior to either arm
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Fig. 1 Individual plasma concentration–time profiles for a the sum of
sunitinib plus SU12662 in combination with pemetrexed/carboplatin on
day 1 of cycle 2 (n=3), b pemetrexed (n=3), c total platinum (n=3), and d
free platinum (n=3). Pemetrexed and carboplatin are shown alone and in
combination with sunitinib at the maximum tolerated dose on Schedule 2/1
Table 6 Responses in patients with NSCLC (all cohorts; n=8)
Patient NSCLC histology Cohorta Best response Rolled over onto
continuation protocol?
Total time on treatment (weeks; up to
July 2011 for continuation patientsb)
1 Unknown Schedule 2/1, dose level B3 Partial response Y 39.6
2 Other CDD, dose level B1 Stable disease ≥8 weeks Y 40
3 Other CDD, dose level B1 Stable disease ≥8 weeks N 20.6
4 Adenocarcinoma Schedule 2/1, MTD (expansion) Stable disease ≥8 weeks Y 20.9
5 Adenocarcinoma Schedule 2/1, MTD (expansion) Stable disease ≥8 weeks N 21.7
6 Bronchioloalveolar Schedule 2/1, MTD (expansion) Stable disease ≥8 weeks N 8.6
7 Adenocarcinoma Schedule 2/1, MTD (expansion) Progressive disease N 8.6
8 Unknown Schedule 2/1, MTD (expansion) Not evaluable N 2.1
CDD continuous daily dosing; NSCLC non-small cell lung cancer
a Dose levels are described in Table 1
bAll rollover patients were still alive at time of data collection
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37.5 mg/day CDD schedule and the combination was associ-
ated with greater hematologic toxicity than either agent alone.
This phase I study established the MTD and overall safety
of the triple combination of sunitinib plus pemetrexed and
carboplatin in patients with advanced solid malignancies. The
MTD on Schedule 2/1 was determined to be sunitinib
37.5 mg/day + pemetrexed 500 mg/m2 q3w + carboplatin
AUC=5 mg·min/ml q3w. The MTD cohort was expanded to
further explore the feasibility, tolerability, and early activity of
this triple combination for the treatment of advanced NSCLC
or mesothelioma. The MTD on the CDD schedule was not
established, as the first dose level tested on this schedule
(sunitinib 37.5 mg/day + pemetrexed 400 mg/m2 q3w +
carboplatin AUC=5 mg·min/ml) was poorly tolerated due to
myelosuppression. As preclinical models and data on mini-
mum inhibitory concentrations suggest that the minimum
effective dose is in the range of 37.5 mg/day [2], it was not
felt that the exploration of a lower dose schedule would lead to
clinically significant activity, considering the need to use
suboptimal doses of each individual drug and the clinical
experience of other groups using sunitinib alone or in combi-
nation with other chemotherapy regimens [36, 37]. Although
there were no PK interactions, toxicities appeared additive
(particularly in the form of myelosuppression), suggesting
overlapping pharmacodynamic effects. It should be noted that
full PK profiles for sunitinib, SU12662, pemetrexed, and
carboplatin were only obtained from the last 3 patients in the
Schedule 2/1 MTD cohort. In the investigators’ judgment, the
drug was not sufficiently tolerated to proceed with dose esca-
lation and lower doses would not provide a clinical benefit.
However, data from these 3 patients were consistent with
historical controls from another study in similar patient pop-
ulations which did not indicate major discrepancies. There is
no preclinical evidence suggesting drug–drug interactions,
and the pharmacologic profiles of pemetrexed, sunitinib and
carboplatin do not predict any elimination interactions when
the drugs are used in combination. Sunitinib is metabolized
primarily by CYP3A4, which does not play a role in the
elimination of carboplatin or pemetrexed. Furthermore,
drug–drug interactions at the absorption level can be ruled
out as carboplatin and pemetrexed were administered
intravenously.
The Schedule 2/1MTDwas generally tolerable and clinically
manageable on both sunitinib treatment schedules, with most
non-hematologic toxicities being mild or moderate (grade 1 or
2), and similar to those reportedwith either single-agent sunitinib
or pemetrexed combined with carboplatin in advanced NSCLC
[12, 13, 38].
Myelosuppression was a common toxicity on the 2/1 dos-
ing schedule, as anticipated. Sunitinib as a single agent has
been associated with myelosuppression in a small proportion
of patients [17, 18, 39]. One possible explanation is the
inhibition of c-KIT, FLT3, and colony-stimulating factor
receptor (c-fms), which may play a role in recovery of blood
cells following myelosuppressive chemotherapy [40].
Hematologic toxicities such as thrombocytopenia and ane-
mia are common AEs of treatment with carboplatin and
pemetrexed monotherapy. In the current study, hematologic
toxicities occurred at a greater rate than expected with
carboplatin and pemetrexed alone [38, 41]. The DLTs and
MTD were determined during the first cycle of treatment;
however, the initial tolerability of these doses was not uni-
formly sustained, as most patients at the Schedule 2/1 MTD
required subsequent sunitinib dose delays or reductions (75 %
and 50 %, respectively). A median of 5.0 (2–6) cycles of the
triple combination was administered in the original Schedule
2/1 MTD cohort, and a median of 3.5 (1–4) cycles was
administered in the expansion cohort, which compared favor-
ably with the cycles reported previously for combinations of
pemetrexed with platinum agents (a median of 3 cycles of
pemetrexed combined with cisplatin or carboplatin has been
reported in previously treated patients with NSCLC [42]).
Pharmacokinetic analyses revealed no clinically significant
drug–drug interactions following co-administration of
sunitinib with pemetrexed plus carboplatin.
The toxicity of the combination was broadly similar to previ-
ous reports of sunitinib plus other types of chemotherapy.
Myelosuppression, fatigue, and diarrhea occurred frequently
and often led to dose adjustments in studies of sunitinib com-
bined with paclitaxel [43, 44], pemetrexed [45], carboplatin/
paclitaxel/bevacizumab [37], gemcitabine/cisplatin [40],
FOLFIRI [46], or modified FOLFOX6 [47]. Significant toxic-
ities have also been observedwith otherVEGFR-TKIs combined
with chemotherapy. Rates of hematological toxicities and diar-
rhea were elevated in studies of sorafenib combined with
docetaxel/cisplatin [48], gemcitabine/cisplatin [49], or
paclitaxel/carboplatin [50]. Similarly, hematologic abnormalities
and diarrhea were commonly observed when axitinib was com-
bined with FOLFIRI [51] or docetaxel [52], and the combination
of axitinib plus bevacizumab and FOLFOX was reported to
markedly raise the incidence of hypertension [51].
In the current study, the ORR on Schedule 2/1 was 4/21
(19%). Given the small number of evaluable patients, and that
responses were observed in patients with different tumor
types, it is not possible to draw a definitive conclusion on
the response rate. However, the observed rate compares fa-
vorably with the ORR for single-agent pemetrexed (4 % [22])
and carboplatin plus pemetrexed (9 % [39]) observed in larger
studies. Of the three patients with NSCLC who entered the
continuation study, one patient with NSCLC NOS had a
partial response (lasting 6.9 months) and two patients with
NSCLC NOS and adenocarcinoma maintained stable disease
for 7.9 and 3.5 months, respectively.
In summary, although the MTD of sunitinib on Schedule 2/1
in combination with pemetrexed and carboplatin was
established, dose adjustments were often required as a result of
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myelosuppression, especially in patients with NSCLC,making it
difficult to maintain a pharmacologically active sunitinib dose.
Although one response was observed in a patient with NSCLC
started at the highest sunitinib dose (50 mg), this dose could not
be sustained in this patient group. However, 37.5 mg was better
tolerated in patients with other tumor types, and clinical re-
sponses were observed in patients with esophageal carcinoma,
breast cancer, and gastric carcinoma. Further exploration of this
combination in solid tumors is warranted.
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